|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
ATE179862T1
(de)
|
1989-07-06 |
1999-05-15 |
Univ California |
Rezeptoren für fibroblasten-wachstumsfaktoren
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
US6323316B1
(en)
|
1996-06-18 |
2001-11-27 |
The United States Of America As Represented By The Secretary Of The Department Of And Human Services |
Fibroblast growth factor receptor activating gene 1 and related compositions and methods
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
DE69840412D1
(de)
|
1997-10-31 |
2009-02-12 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
AU3369999A
(en)
|
1998-04-02 |
1999-10-25 |
Genentech Inc. |
Antibody variants and fragments thereof
|
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
|
WO2000025803A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparations
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
EP1185559A2
(en)
|
1999-04-28 |
2002-03-13 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
CA2424602C
(en)
|
2000-10-06 |
2012-09-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-producing cell
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
MXPA04003798A
(es)
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
|
CN101357943A
(zh)
*
|
2001-10-25 |
2009-02-04 |
杰南技术公司 |
糖蛋白组合物
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
WO2003063893A2
(en)
|
2002-01-31 |
2003-08-07 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Fgfr agonists
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
|
PL373256A1
(en)
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
|
JPWO2003085119A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
AU2003236017B2
(en)
|
2002-04-09 |
2009-03-26 |
Kyowa Kirin Co., Ltd. |
Drug containing antibody composition
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
KR100973564B1
(ko)
*
|
2003-05-02 |
2010-08-03 |
젠코어 인코포레이티드 |
최적화된 Ｆｃ 변이체 및 그의 제조 방법
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
|
SI1680140T1
(sl)
*
|
2003-10-16 |
2011-08-31 |
Imclone Llc |
Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
|
|
DK2330201T3
(en)
|
2003-10-22 |
2017-07-24 |
Keck Graduate Inst |
PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY
|
|
NO347530B1
(no)
|
2003-11-05 |
2023-12-11 |
Roche Glycart Ag |
Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning.
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
|
EP1773305A2
(en)
|
2004-05-25 |
2007-04-18 |
Yale University Corporation |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
ATE454455T1
(de)
|
2005-01-27 |
2010-01-15 |
Five Prime Therapeutics Inc |
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
|
|
SG170006A1
(en)
*
|
2005-02-18 |
2011-04-29 |
Medarex Inc |
Monoclonal antibodies against cd30 lacking fucosyl residues
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
US7890267B2
(en)
|
2006-03-31 |
2011-02-15 |
Ordway Research Institute |
Prognostic and diagnostic method for cancer therapy
|
|
WO2007134210A2
(en)
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
|
CA2655246A1
(en)
*
|
2006-06-09 |
2007-12-21 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
EP2046384A4
(en)
|
2006-06-15 |
2009-12-02 |
Fibron Ltd |
ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
EP2066694B1
(en)
|
2006-09-29 |
2015-11-04 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
US8394927B2
(en)
|
2006-11-03 |
2013-03-12 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
|
US20090068110A1
(en)
|
2006-12-22 |
2009-03-12 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
JP5071942B2
(ja)
|
2007-01-24 |
2012-11-14 |
協和発酵キリン株式会社 |
エフェクター活性が増強された遺伝子組換え抗体組成物
|
|
BRPI0809137A2
(pt)
|
2007-03-23 |
2016-07-26 |
Translational Genomics Res Inst |
métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar
|
|
WO2008121876A2
(en)
*
|
2007-03-28 |
2008-10-09 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
WO2009052830A1
(en)
|
2007-10-22 |
2009-04-30 |
Genmab A/S |
Novel antibody therapies
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US20110059091A1
(en)
|
2008-02-04 |
2011-03-10 |
Xiao-Jia Chang |
Inhibitors of oncogenic isoforms and uses thereof
|
|
US8688158B2
(en)
|
2008-03-26 |
2014-04-01 |
Nec Corporation |
Radio resource control method, radio station apparatus, recording medium storing radio station control program, and radio communication system
|
|
CA2727247A1
(en)
*
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
LT2842573T
(lt)
|
2008-11-07 |
2017-12-11 |
Galaxy Biotech, Llc |
Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2
|
|
WO2011025814A1
(en)
|
2009-08-25 |
2011-03-03 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
CN102666874B
(zh)
*
|
2009-10-07 |
2016-06-01 |
宏观基因有限公司 |
由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
|
|
EP2488554B1
(en)
*
|
2009-10-14 |
2019-07-24 |
Humanigen, Inc. |
Antibodies to epha3
|
|
CN102762221A
(zh)
|
2010-01-14 |
2012-10-31 |
耶鲁大学 |
受体酪氨酸激酶(rtk)的抑制剂及其使用方法
|
|
US9140689B2
(en)
|
2010-03-14 |
2015-09-22 |
Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
BR112012028764A2
(pt)
|
2010-05-11 |
2017-03-14 |
Aveo Pharmaceuticals Inc |
anticor-pos antifgfr2
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
EP2603521A4
(en)
|
2010-08-12 |
2014-10-01 |
Attogen Inc |
ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
|
|
US20120258496A1
(en)
*
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
EP3828205A1
(en)
*
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
US20150023989A1
(en)
|
2011-12-14 |
2015-01-22 |
Seattle Genetics, Inc. |
New antibody drug conjugates (adcs) and the use thereof
|
|
DK2831110T3
(en)
*
|
2012-03-30 |
2018-08-06 |
Univ California |
Anti-EMP2 therapy to reduce cancer stem cells
|
|
JP6188681B2
(ja)
|
2012-04-09 |
2017-08-30 |
第一三共株式会社 |
抗ｆｇｆｒ２抗体
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
KR102418979B1
(ko)
|
2012-05-15 |
2022-07-11 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
|
|
CN104619840A
(zh)
|
2012-07-05 |
2015-05-13 |
日本国立癌症研究中心 |
Fgfr2融合基因
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
AU2014207342C1
(en)
|
2013-01-18 |
2019-04-04 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
HK1213817A1
(zh)
|
2013-05-01 |
2016-07-15 |
戊瑞治疗有限公司 |
治療癌症的方法
|
|
EP3800266A1
(en)
|
2013-06-13 |
2021-04-07 |
University Of South Australia |
Methods for detecting prostate cancer
|
|
CA2915665C
(en)
|
2013-08-01 |
2020-07-28 |
Five Prime Therapeutics, Inc. |
Afucosylated anti-fgfr2iiib antibodies
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
US20170175197A1
(en)
|
2014-01-29 |
2017-06-22 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
WO2017091580A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
|
LT3624837T
(lt)
|
2017-05-16 |
2025-10-10 |
|
Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
|